Kevin Bielamowicz
Overview
Explore the profile of Kevin Bielamowicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landi D, Navai S, Brock R, Fousek K, Nawas Z, Sanber K, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 39973814
The efficacy of CAR T-cells (CART) in solid tumors is limited by immune inhibition. In our study, we observed that effector cytokines mediated the upregulation of the PD-L1 immune-checkpoint in...
2.
Moertel C, Hirbe A, Shuhaiber H, Bielamowicz K, Sidhu A, Viskochil D, et al.
J Clin Oncol
. 2024 Nov;
43(6):716-729.
PMID: 39514826
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults. Methods: ReNeu is an open-label, multicenter, pivotal, phase...
3.
Bielamowicz K, Dimitrion P, Abla O, Bomken S, Campbell P, Collin M, et al.
Cancer
. 2024 Apr;
130(14):2416-2439.
PMID: 38687639
Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations...
4.
Saulnier Sholler G, Bergendahl G, Lewis E, Kraveka J, Ferguson W, Nagulapally A, et al.
Genome Med
. 2024 Feb;
16(1):28.
PMID: 38347552
Background: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and...
5.
Das A, Fernandez N, Levine A, Bianchi V, Stengs L, Chung J, et al.
Cancer Discov
. 2023 Oct;
14(2):258-273.
PMID: 37823831
Significance: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological...
6.
Burger B, Pertzborn M, Bielamowicz K, Ghazala Z
Breathe (Sheff)
. 2023 Sep;
19(3):230045.
PMID: 37719236
https://bit.ly/3NFAk9S.
7.
Guzman G, Reed M, Bielamowicz K, Koss B, Rodriguez A
Curr Oncol Rep
. 2023 Feb;
25(5):479-489.
PMID: 36853475
Purpose Of Review: This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will...
8.
Saulnier-Sholler G, Duda D, Bergendahl G, Ebb D, Snuderl M, Laetsch T, et al.
Clin Cancer Res
. 2022 Jul;
28(18):3950-3957.
PMID: 35833850
Purpose: Placental growth factor (PlGF) and its receptor neuropilin 1 are elevated in malignant embryonal tumors and mediate tumor progression by promoting cell proliferation, survival, and metastasis. TB-403 is a...
9.
Mak D, Laperriere N, Ramaswamy V, Bouffet E, Murray J, McNall-Knapp R, et al.
Neurooncol Adv
. 2022 Jan;
3(1):vdab158.
PMID: 34988448
Background: The goal of this study was to evaluate extent of surgical resection, and timing and volume of re-irradiation, on survival for children with locally recurrent ependymoma. Methods: Children with...
10.
Aldrich K, Horne V, Bielamowicz K, Sonabend R, Scheurer M, Paulino A, et al.
J Neurooncol
. 2021 Oct;
155(1):93-100.
PMID: 34596831
Background: Endocrine deficiencies are common following Craniospinal irradiation (CSI) in children with brain tumors, but empirical data comparing outcomes following proton (PRT) and photon radiation therapy (XRT) are limited. Methods:...